Like other AAS, boldenone is an agonist of the androgen receptor (AR).  The activity of boldenone is mainly anabolic , with a low androgenic potency. Boldenone will increase nitrogen retention, protein synthesis, increases appetite and stimulates the release of erythropoietin in the kidneys.  Boldenone was synthesized in an attempt to create a long-acting injectable metandienone , for androgen deficiency disorders. Boldenone acts similar to metandienone with fewer adverse androgenic effects. [ medical citation needed ] Although commonly compared to nandrolone , boldenone lacks progesterone receptor interaction and associated progestogenic side effects.
Ligand Pharmaceuticals has patents filed for the manufacture and therapeutic use of certain compounds occupying several stated chemical structures, which are intended for use as selective androgen receptor modulators. The patent is filed under the following designations: US8519158 B2, US8865918, US9359285, US20070254875, US20140005186, US20150099720, and WO2005090282A1. The patents will expire on March 12, 2025. These patents effectively protect any future capitalization upon VK5211 in the market by Viking and Ligand through their licensing agreement.